Avidity Biosciences has appointed Joseph Baroldi to serve as its chief operating officer. He joins San Diego-based Avidity from Ionis Pharmaceuticals (NASDAQ: [[ticker:IONS]]), where he was vice president of business development. Avidity, which closed a $100 million Series C round of funding in November, is developing antisense-oligonucleotide antibody drugs. Its lead therapeutic candidate is a … Continue reading “Ionis Pharma’s Joseph Baroldi Joins Avidity as Chief Operating Officer”
Millendo Picks Poxel’s Arbet-Engels for Chief Medical Officer Post
Millendo Therapeutics (NASDAQ: [[ticker:MLND]]) has appointed Christophe Arbet-Engels to serve as its chief medical officer, the same position he held most recently at Poxel Pharmaceuticals. Arbet-Engels’s experience also includes positions at Biogen (NASDAQ: [[ticker:BIIB]]), Boehringer Ingelheim, Roche, Merck (NYSE: [[ticker:MRK]]), Aventis and Ligand Pharmaceuticals (NASDAQ: [[ticker:LGND]]). Millendo’s most advanced drug candidate, livoletide, is being developed … Continue reading “Millendo Picks Poxel’s Arbet-Engels for Chief Medical Officer Post”
Ligand’s Icagen Deal Brings Neuro, CF Assets Plus Partnering Potential
Ligand Pharmaceuticals is adding neurological disease and cystic fibrosis programs to its pipeline through a deal to acquire assets from drug discovery company Icagen. San Diego-based Ligand (NASDAQ: [[ticker:LGND]]) is paying $15 million up front for the “core assets” of Icagen’s Durham, NC operations. The neuroscience program is being developed under a partnership with Roche … Continue reading “Ligand’s Icagen Deal Brings Neuro, CF Assets Plus Partnering Potential”
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
CRISPR, capacity, and consolidation powered the cell and gene therapy space in 2019, but a proactive focus on patient access topped Falcon Therapeutics CEO Susan Nichols’ annual roundup. In what has become one of the most anticipated presentations at the Phacilitate Leaders World Conference, Susan Nichols, CEO of private North Carolina-based cell therapy firm Falcon … Continue reading “CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019”
Encoded Therapeutics Adds Rico, Moorhead to C-Suite
Gene therapy developed Encoded Therapeutics has appointed Salvador Rico to serve as its chief medical officer. Rico joins South San Francisco-based Encoded from Audentes Therapeutics, where he was senior vice president of clinical development. Audentes was recently acquired by Astellas in a $3 billion deal. In other moves, Encoded promoted Martin Moorhead from head of … Continue reading “Encoded Therapeutics Adds Rico, Moorhead to C-Suite”
Pfizer Veteran Abraham Joins Vividion as Chief Scientific Officer
Vividion Therapeutics has appointed Robert Abraham to serve as its chief scientific officer. He joins the San Diego-based drug developer after 10 years at Pfizer (NYSE: [[ticker:PFE]]), where he was most recently senior vice president and group head, oncology research and development. He came to Pfizer through its 2009 acquisition of Wyeth. Vividion is developing … Continue reading “Pfizer Veteran Abraham Joins Vividion as Chief Scientific Officer”
Lyndra Taps Pacira’s Richard Stanton for Chief Medical Officer Role
Richard Stanton has joined Lyndra Therapeutics as chief medical officer, the same role he held most recently at Pacira Pharmaceuticals. Lyndra is developing drug delivery technology that turns daily medications into extended-release formulations via a mechanism that keeps a drug in the stomach longer. Last year, the Watertown, MA-based company raised $55 million in Series … Continue reading “Lyndra Taps Pacira’s Richard Stanton for Chief Medical Officer Role”
Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened.
Pfizer and Merck are each cutting ties with a smaller clinical-stage biotech after experimental drugs being developed under separate alliances fell short in human testing. Pfizer (NYSE: [[ticker:PFE]]) is walking away from a partnership with GlycoMimetics (NASDAQ: [[ticker:GLYC]]) a Rockville, MD-based company developing drugs for diseases where carbohydrates play a role. In 2011, Pfizer paid … Continue reading “Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened.”
FDA Clinical Hold Stops LogicBio’s Gene Editing Study Before It Starts
The FDA has placed a clinical hold on a LogicBio Therapeutics application to begin human testing of its experimental gene-editing therapy for a rare, inherited liver disorder. LogicBio (NASDAQ: [[ticker:LOGC]]) disclosed the clinical hold for its gene-editing therapy, LB-001, after Monday’s market close. The Cambridge, MA-based biotech said that the hold concerns “certain clinical and … Continue reading “FDA Clinical Hold Stops LogicBio’s Gene Editing Study Before It Starts”
Wave Life Sciences’ Stumble in Duchenne Leads to 22% Staff Layoff
Wave Life Sciences is cutting about 22 percent of its staff as part of a corporate shakeup that follows the company’s decision to stop work on its Duchenne muscular dystrophy programs. Singapore-based Wave (NASDAQ: [[ticker:WVE]]), which has its US operations in Cambridge, MA, said in a Feb. 6 regulatory filing it expects to have notified … Continue reading “Wave Life Sciences’ Stumble in Duchenne Leads to 22% Staff Layoff”
Biohaven Drug Fails Anxiety Study, Data in OCD and More Still to Come
An experimental Biohaven Pharmaceutial therapy intended to treat anxiety has failed in a late-stage study, the first of four shots that the company is taking with the drug to try to address neurological disorders. The results released Monday for Biohaven (NASDAQ: [[ticker:BHVN]]) drug troriluzole were for generalized anxiety disorder, a persistent feeling of worry or … Continue reading “Biohaven Drug Fails Anxiety Study, Data in OCD and More Still to Come”
Eli Lilly, Roche Drugs Fail to Move Needle in Genetically Driven Alzheimer’s
Two experimental drugs from Eli Lilly and Roche have failed a clinical trial testing them as treatments for a form of Alzheimer’s disease caused by certain genetic mutations, the companies reported Monday. The study, sponsored by Washington University, tested the drugs in patients who have an early onset, inherited form of Alzheimer’s called autosomal dominant. … Continue reading “Eli Lilly, Roche Drugs Fail to Move Needle in Genetically Driven Alzheimer’s”
Takeda’s Peng Lu Joins Pharvaris as Chief Medical Officer
Pharvaris has appointed Peng Lu to serve in the newly created position of chief medical officer. Lu joins the Leiden, Netherlands-based drug developer from Takeda Pharmaceutical (NYSE: [[ticker:TAK]]), where she was vice president and global program lead for rare diseases. Lu will be based in Pharvaris’s Boston office. The company’s lead drug candidate, PHA121, is … Continue reading “Takeda’s Peng Lu Joins Pharvaris as Chief Medical Officer”
Complexa Appoints Elisabeth Leiderman Chief Business Officer
Elisabeth Leiderman has joined Complexa as chief business officer. She was most recently senior vice president and head of corporate development for Fortress Biotech (NASDAQ: [[ticker:FBIO]]). Berwyn, PA-based Complexa’s lead drug candidate, CXA-10, is in Phase 2 testing for focal segmental glomerulosclerosis and pulmonary arterial hypertension.
Bio Roundup: POTUS on Prices, a16z’s Fund, Aimmune’s Approval & More
The president’s State of the Union address was wide-ranging, as they tend to be, but those who tuned in heard mention of two hot health policy topics: price transparency and drug pricing reform. President Trump asserted that an executive order he signed last year directing various federal agencies to come up with new rules requiring … Continue reading “Bio Roundup: POTUS on Prices, a16z’s Fund, Aimmune’s Approval & More”
Myriad Genetics Exec Capone Resigns, Riggsbee Named Interim CEO
Longtime Myriad Genetics (NASDAQ: [[ticker:MYGN]]) president and CEO Mark Capone has resigned. The Salt Lake City-based molecular diagnostic company said Myriad and Capone—who has been with the company for 17 years—mutually agreed it was the right time for a leadership transition. Bryan Riggsbee, Myriad’s chief financial officer, was appointed interim president and CEO. He will … Continue reading “Myriad Genetics Exec Capone Resigns, Riggsbee Named Interim CEO”
Ichnos Sciences Appoints Gabriela Gruia as Chief Development Officer
Ichnos Sciences named Gabriela Gruia as its chief development officer. Gruia was most recently senior vice president and head of regulatory affairs for the Novartis (NYSE: [[ticker:NVS]]) oncology business. Her experience includes previous roles at Pharmacia and Pfizer (NYSE: [[ticker:PFE]]). The Paramus, NJ, company is a spinout of Indian company Glenmark Pharmaceuticals that debuted in … Continue reading “Ichnos Sciences Appoints Gabriela Gruia as Chief Development Officer”
Novartis’s Wotling to Join DBV as Chief Technical Operations Officer
DBV Technologies (NASDAQ: [[ticker:DBVT]]) has appointed Pascal Wotling to serve as its chief technical operations officer. He worked most recently at Novartis (NYSE: [[ticker:NVS]]), where he was head of external supply operations for the Asia-Pacific, Middle East, and Africa. He will start at Bagneux, France-based DBV on April 1. DBV is awaiting an FDA decision … Continue reading “Novartis’s Wotling to Join DBV as Chief Technical Operations Officer”
Aerami Therapeutics Appoints Timm Crowder Chief Operating Officer
Timm Crowder has joined Aerami Therapeutics as its chief operating officer, the same role he held most recently at Spyryx Biosciences. His experience also includes positions at GlaxoSmithKline (NYSE: [[ticker:GSK]]) and Oriel Therapeutics. Durham, NC-based Aerami is developing aerosol formulations of drugs that are administered via its “smart inhaler” technology. The company’s lead product candidate, … Continue reading “Aerami Therapeutics Appoints Timm Crowder Chief Operating Officer”
Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer
Cell therapies have reached the market as a new treatment option for some cancers. But the scientists of Sonoma Biotherapeutics say this approach also holds promise for autoimmune disorders, and the biotech startup has unveiled $40 million in financing to develop its technology. The investors in Sonoma’s Series A round of funding include Lyell Immunopharma, … Continue reading “Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer”
Scripps Research’s Calibr to Test “Switchable” CAR-T in Clinical Trial
Scripps Research is charting new territory with its Calibr division, a drug discovery and drug development group within the research institute that is advancing its own experimental treatments. This week Calibr announced it had received the agency’s go-ahead to move a CAR-T cell therapy it has been evaluating for the treatment of certain blood cancers, … Continue reading “Scripps Research’s Calibr to Test “Switchable” CAR-T in Clinical Trial”
Xcelerating Life Sciences New York
Stay at the forefront of New York’s burgeoning life science ecosystem that is fueling today’s biotech investment and & partnership opportunities New York has been laying the groundwork to welcome a state-of-the-art biopharma community with the space, financial backing, and intellectual capital for building companies. Medical centers, academic institutions, and government support are all being … Continue reading “Xcelerating Life Sciences New York”
Xcelerating Life Sciences Philadelphia (interactive online event)
Engage with Philadelphia’s growing cell and gene therapy ecosystem, explore promising investment and partnership opportunities, and align the latest trends and technologies with your business Philadelphia is committed to becoming the next center for biotech innovation. The area already offers a strong biopharma foundation, world-class medical centers, academic institutions, entrepreneurial and partnership opportunities, and room … Continue reading “Xcelerating Life Sciences Philadelphia (interactive online event)”
Early Bird Sale Ending for San Diego’s Xcelerating Life Sciences Conference
This is the last week to register at the lowest rate for March 18’s Xcelerating Life Sciences: Biomedical Breakthroughs in Precision Medicine & Genomics conference at the Takeda Research facility in San Diego. Hurry, our $99 early bird sale ends this Friday, Feb. 7 at midnight. Join Xconomy as we explore how the investment paradigm … Continue reading “Early Bird Sale Ending for San Diego’s Xcelerating Life Sciences Conference”
Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered
Gene editing biotech Beam Therapeutics raised $180 million in its initial public offering Wednesday after offering 48 percent more shares than it initially anticipated. Beam, which was slated to begin trading Thursday on the Nasdaq exchange under the stock symbol “BEAM,” sold 9.25 million shares, up from the 6.25 million it said it planned to … Continue reading “Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered”
Coda Bio Acquires Drug Candidates to Pair With Engineered Receptors
To have a therapeutic effect, drugs need to bind to proteins. But since it isn’t always possible to find an appropriate receptor, Coda Biotherapeutics is designing receptors, which it plans to deliver via engineered viruses, that respond only to a specific drug. On Wednesday the South San Francisco-based biotech announced it acquired a company called … Continue reading “Coda Bio Acquires Drug Candidates to Pair With Engineered Receptors”
Aimmune Gets $200M From Nestlé; Licenses Food Allergy Drug Candidate
Last week the FDA approved an Aimmune Therapeutics drug for children with peanut allergies, the first oral immunotherapy for a food allergy to get the agency’s nod. On Wednesday the Brisbane, CA-based biotech announced that one of its backers, Nestlé Health Science, had made a new $200 million equity investment that it will use to … Continue reading “Aimmune Gets $200M From Nestlé; Licenses Food Allergy Drug Candidate”
Merck Charts an R&D-Focused Course Starting With a $6.5B Spinoff
Merck is corralling products representing $6.5 billion in sales and spinning them off into a separate company, a strategic bet that focusing the remaining business on developing innovative new medicines will drive future growth. The new company will take Merck’s women’s health business, older medicines that have lost patent protection, and biosimilars—drugs that are close … Continue reading “Merck Charts an R&D-Focused Course Starting With a $6.5B Spinoff”
Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA
Titan Medical didn’t meet its goal of submitting its robotic surgical system for FDA clearance by the end of 2019. Now the company says it needs another $85 million to get its medical device to the finish line or it might have to put itself up for sale. The robotic systems developer spelled out the … Continue reading “Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA”
Verily, Santen See Ophthalmology Opportunity Via New Joint Venture
Verily, the life sciences spinout of Google parent Alphabet, has inked a deal with a Japanese ophthalmology company to develop digital tools and technologies to improve eye health. Santen Pharmaceutical, which is based in Osaka, has a global industrial and commercial ophthalmology business. Teaming up with Verily will enable it to apply the South San … Continue reading “Verily, Santen See Ophthalmology Opportunity Via New Joint Venture”
Amylyx Pharmaceuticals Names Jeffrey Trigilio Chief Financial Officer
Amylyx Pharmaceuticals has appointed Jeffrey Trigilio to serve as its first chief financial officer. Trigilio was most recently vice president of finance at cell therapy company BlueRock Therapeutics. His previous experience includes time at Alexion Pharmaceuticals (NASDAQ: [[ticker:ALXN]]). Amylyx, which is based in Cambridge, MA, is developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s … Continue reading “Amylyx Pharmaceuticals Names Jeffrey Trigilio Chief Financial Officer”
Epirium Bio Names BioMarin’s Somaratne Its Chief Medical Officer
Epirium Bio, which recently raised $85 million to develop new drugs for disorders associated with mitochondrial depletion, appointed Ransi Somaratne as its chief medical officer. Somaratne was most recently core team leader for the BioMarin Pharmaceutical (NASDAQ: [[ticker:BMRN]]) hemophilia A gene therapy program, where he led the group that has asked the FDA to review … Continue reading “Epirium Bio Names BioMarin’s Somaratne Its Chief Medical Officer”
$750M Fund Looks to Software Sector to Drive Future of Biotech
Andreessen Horowitz (a16z), a Silicon Valley venture capital firm best known for backing high-flying software startups such as Facebook, Lyft, and Skype, is doubling down on its foray into biotech-related bets. A16z on Tuesday revealed it has raised $750 million for its third Bio Fund. The fund is bigger than its first two combined and … Continue reading “$750M Fund Looks to Software Sector to Drive Future of Biotech”
Portola Picks Adamas Pharma’s Patni for Chief Medical Officer Role
Rajiv Patni has joined Portola Pharmaceuticals (NASDAQ: [[ticker:PTLA]]) as executive vice president and chief medical officer. He comes to South San Francisco-based Portola from Adamas Pharmaceuticals (NASDAQ: [[ticker:ADMS]]), where he was chief medical officer. Patni’s experience also includes positions at Ocera Therapeutics, Actelion Pharmaceuticals, Roche, and Pfizer (NYSE: [[ticker:PFE]]). Portola has commercialized two FDA-approved therapies: … Continue reading “Portola Picks Adamas Pharma’s Patni for Chief Medical Officer Role”
BioMarin’s Spiegelman Steps Down, Mueller Steps Up as Acting CFO
Dan Spiegelman, chief financial officer of BioMarin Pharmaceutical (NASDAQ: [[ticker:BMRN]]) for the past eight years, has stepped down from his executive role. According to a securities filing, the job change took effect on Jan. 29. The San Rafael, CA-based rare disease drug developer says Spiegelman will continue as an employee and senior advisor until Sept. … Continue reading “BioMarin’s Spiegelman Steps Down, Mueller Steps Up as Acting CFO”
Bristol-Myers, BioMotiv Pact Leads to a New Fibrosis-Focused Startup
Bristol-Myers Squibb is still digesting the commercialized and clinical-stage assets that came with its $74 billion acquisition of Celgene, but the pharmaceutical giant has also been making moves to feed its pipeline with compounds at earlier points of development. An alliance that Bristol struck up with pharmaceutical accelerator BioMotiv last year now has its first … Continue reading “Bristol-Myers, BioMotiv Pact Leads to a New Fibrosis-Focused Startup”
Passage Bio Plans IPO as Three Gene Therapies Approach the Clinic
A year ago Passage Bio launched with $115.5 million and plans to advance a handful of gene therapies discovered at the University of Pennsylvania. Now the Philadelphia-based biotech is preparing to join the public markets and raise millions more to move its three lead programs into the clinic. Want more cell and gene therapy content? … Continue reading “Passage Bio Plans IPO as Three Gene Therapies Approach the Clinic”
Insmed Drug for Rare Pulmonary Disorder Meets Phase 2 Goals
Rare disease drug developer Insmed on Monday revealed data from a mid-stage trial of its daily pill for adults with non-cystic fibrosis bronchiectasis, a severe chronic pulmonary disorder with no FDA-approved therapies. Patients with chronic inflammatory lung diseases end up with an overabundance of white blood cells called neutrophils in their airways. The Insmed drug, … Continue reading “Insmed Drug for Rare Pulmonary Disorder Meets Phase 2 Goals”
CytomX Appoints Alison Hannah Senior VP and Chief Medical Officer
Alison Hannah has joined CytomX (NASDAQ: [[ticker:CTMX]]) as senior vice president and chief medical officer. Hannah was most recently a consultant to pharmaceutical and biotechnology companies. Her experience also includes positions at Sugen and Quintiles. South San Francisco-based CytomX is developing a type of cancer treatment it calls a “Probody drug.” The company’s pipeline includes … Continue reading “CytomX Appoints Alison Hannah Senior VP and Chief Medical Officer”
Boston Pharmaceuticals Picks NIBR’s Basson for Chief Medical Officer
Boston Pharmaceuticals has appointed Craig Basson to serve as its chief medical officer. He joins the Cambridge, MA, company from the Novartis Institutes for Biomedical Research (NIBR), where he was global head of translational medicine for the cardiovascular and metabolic therapeutic areas. Before joining Novartis, Basson was a professor of cardiology and internal medicine at … Continue reading “Boston Pharmaceuticals Picks NIBR’s Basson for Chief Medical Officer”
United Therapeutics Drug Flunks Small Cell Lung Cancer Clinical Trial
An effort to expand use of a United Therapeutics oncology drug to the treatment of small cell lung cancer has fallen short. United Therapeutics (NASDAQ: [[ticker:UTHR]]) announced Monday that a Phase 2/3 study testing dinutuximab (Unituxin) did not meet the main goal of helping patients live longer. The Silver Spring, MD-based company says full data … Continue reading “United Therapeutics Drug Flunks Small Cell Lung Cancer Clinical Trial”
Discovery Labs Converts ex-GSK King of Prussia Site into R&D “Colony”
The MLP Ventures-funded Discovery Labs says it is “bending the rules” in its efforts to stimulate R&D at the former GlaxoSmithKline site through a limited governance financial model. In April 2018, GlaxoSmithKline (NYSE: [[ticker:GSK]]) sold its R&D campus in King of Prussia, PA, to private Philadelphia-based life science and real estate investment company MLP Ventures … Continue reading “Discovery Labs Converts ex-GSK King of Prussia Site into R&D “Colony””
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
An Aimmune Therapeutics drug developed to treat peanut allergy won FDA approval late Friday—the first time the agency has approved an oral immunotherapy for a food allergy. The Aimmune (NASDAQ: [[ticker:AIMT]]) drug, Palforzia, was developed to desensitize patients to peanuts. The FDA decision covers patients between the ages of 4 and 17 who have a … Continue reading “Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy”
Arcutis Bio Raises $159M in Upsized IPO to Test Skin Disease Drugs
Arcutis Biotherapeutics raised about $159 million from its IPO, offering 1.6 million more shares than anticipated and pricing at the high end of its planned range. The Westlake Village, CA-based biotech sold about 9.4 million of its shares at $17 apiece. Arcutis (NASDAQ: [[ticker:ARQT]]) shares began trading Friday. The stock price closed at $21.80, up … Continue reading “Arcutis Bio Raises $159M in Upsized IPO to Test Skin Disease Drugs”
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
If this week is any indication, the steady march of life science companies to Wall Street will continue in 2020. Black Diamond Therapeutics is leading the way, having raised $201 million from its IPO. In its first day of trading, the cancer drug developer watched its shares soar more than 108 percent. Black Diamond’s stock … Continue reading “Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More”
Moderna Adds Takeda’s Melanie Ivarsson as Chief Development Officer
Moderna (NASDAQ: [[ticker:RNA]]) named Melanie Ivarsson as its chief development officer. Ivarsson was most recently vice president, head of clinical operations at Takeda Pharmaceuticals (NYSE: [[ticker:TAK]]). Her previous experience includes serving as senior director, head of clinical strategy and operations at Pfizer (NYSE: [[ticker:PFE]]), and roles within the early clinical development group at Eli Lilly (NYSE: … Continue reading “Moderna Adds Takeda’s Melanie Ivarsson as Chief Development Officer”
Disc Medicine Adds Longtime Acceleron Pharma Exec as New CEO
Disc Medicine appointed John Quisel as its new CEO. Quisel, most recently chief business officer at Acceleron Pharma (NASDAQ: [[ticker:XLRN]]), will start Feb. 25. Quisel will join Disc Medicine after more than a decade at Acceleron Pharma, where he held a variety of roles since joining the company in 2006. He succeeds Disc co-founder Brian MacDonald, … Continue reading “Disc Medicine Adds Longtime Acceleron Pharma Exec as New CEO”
BIO Report: More Work Needed to Improve Diversity at Biotech Firms
Some companies that belong to the Biotechnology Industry Organization (BIO), a large industry trade group, convene diverse hiring committees, seek out representation among their suppliers and vendors, and are led by executives that talk regularly about the importance of an inclusive workforce. Others have no women or people of color as employees, gather no data … Continue reading “BIO Report: More Work Needed to Improve Diversity at Biotech Firms”
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
Mammoth Biosciences set out to develop CRISPR-based diagnostics that could be faster and cheaper than what’s available today. Those diagnostics are still on the way, but Mammoth now has a new piece in its toolbox that could broaden the reach of these tests and expand the startup into therapeutic applications. To support development of these … Continue reading “With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14”
Black Diamond’s Upsized IPO Raises $201M to Advance Its Cancer Drug R&D
A little more than a year ago, Black Diamond Therapeutics unveiled technology that analyzes genetic data to discover new cancer drugs. Today the company has $201 million from an IPO to advance the development of drugs stemming from that technology. Black Diamond priced its IPO late Wednesday, selling 10.5 million shares for $19 apiece. That … Continue reading “Black Diamond’s Upsized IPO Raises $201M to Advance Its Cancer Drug R&D”